





PHARMACEUTICAL 2023

BIOXYTRAN INC Rank 432 of 446

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 187% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 244% points.

The company's Economic Capital Ratio, given in the ranking table, is -412%, being 456% points below the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 295 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 76 |
| Liabilities, Current | 3,663 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 0 |
| Other Expenses | 223 |
| Other Liabilities | 0 |
| Other Net Income | -523 |
| Other Revenues | 0 |
| Property and Equipment | 0 |
| Research and Development | 978 |
| Selling, General and Administrative Expense | 934 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 371 |
| Liabilities | 3,663 |
| Expenses | 2,134 |
| Revenues | 0 |
| Stockholders Equity | -3,293 |
| Net Income | -2,657 |
| Comprehensive Net Income | -2,657 |
| Economic Capital Ratio | -412% |